In-depth coverage of the clinical trials shaping GLP-1, GLP-3, and incretin research — SURMOUNT, SURPASS, STEP, SELECT, and the retatrutide TRIUMPH program. Every quantitative figure is attributed to the named trial or its peer-reviewed publication. Retatrutide and other investigational compounds are not FDA-approved.
Navigating Informed Consent in GLP-3 Clinical TrialsAs a researcher, ensuring informed consent is a critical component of any clinical trial. The GLP-3 trial I led for my fitness business last…
A hepatology clinic reviewing a stack of transient elastography reports this month will find a familiar pattern: F2-F3 fibrosis on biopsy or imaging, elevated liver enzymes, a patient already on…
When the STEP 1 trial (NCT03548935) reported a 14.9% mean body weight reduction with once-weekly subcutaneous semaglutide 2.4 mg at 68 weeks, that figure became a benchmark for GLP-1 obesity…
What the 48-week Phase 2 data on retatrutide reported for weight and glycemic endpoints, with every figure attributed to the published trial. Retatrutide is investigational and not FDA-approved.
When Weight Loss Becomes a Sleep Apnea Treatment Picture a 54-year-old patient — moderately obese, CPAP-dependent for six years, compliance at maybe 60% on a good month. He shows up to a weight…
A Problem That Weight Loss Alone Wasn't Solving Picture a 54-year-old male patient — 118 kg, BMI 38, moderate-to-severe obstructive sleep apnea confirmed by polysomnography. He's been on CPAP for…
Why the Retatrutide Phase 3 Readout Is the Most-Watched Trial in Metabolic Medicine Right Now Imagine running a weight management clinic. Your best patients on semaglutide 2.4 mg hit a wall at…